Effect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 8, 2016, Pages 777-783

  Kalemeera, Francis ^a   Mbango, Christofina ^a   Mubita, Mwangana ^a   Naikaku, Esther ^a   Gaida, Razia ^b   Godman, Brian ^c,d  

^a UNIVERSITY OF NAMIBIA   (Namibia)

^b NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

combination antiretroviral therapy; creatinine clearance; drug utilisation study; Namibia; renal function

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NAMIBIA; NEPHROTOXICITY; RETROSPECTIVE STUDY; SEX DIFFERENCE; BLOOD; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; KIDNEY; KIDNEY FUNCTION TEST;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CREATININE; FEMALE; HIV INFECTIONS; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; NAMIBIA; RETROSPECTIVE STUDIES;

EID: 84978544244     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2016.1202759     Document Type: Article

References (26)

1. S.D.Lawn, A.D.Harries, R.Wood Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opinion HIV AIDS. 2010 Jan;5(1):18–26. doi:10.1097/COH.0b013e328333850f.
2. B.Fernandez-Fernandez, A.B.Montoya-Ferrer, M.D.Sanz, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:1–11. • This paper exposes the pathologic mechanisms of tubulopathy associated with tenofovir, having them categorised into acute and chronic conditions.
3. T.Shafi, M.J.Choi, L.C.Racussen, et al. Ritonavir-Induced acute kidney injury: kidney biopsy findings and review of literature. Clin Nephrol. 2011 Feb;75(01):60–64.•• This paper discusses evidence of kidney injury associated with ritonavir, particularly the tubulopathy. The evidence constitutes the rise of SeCr to higher than normal levels, which drops only when RTV is withdrawn.
4. M.Boffito. From concept to care: pharmacokinetic boosting of protease inhibitors. London: Physicians Research Network, Inc(R), New York City; 2004.
5. Ministry of Health and Socia Sevices. Namibia, in national guidelines for antiretroviral therapy. 4th ed. Windhoek: Ministry of Health and Social Services; 2014. p. 17.
6. K.K.Patel, A.K.Patel, J.K.Patel. Tenofovir-associated renal dysfunction in clinical practice: an observational cohort from western India. Indian J Sex Transm Dis. 2010 Jan-Jun;31(1):30–34.•• In the cohort, the researchers observed mild and moderate renal impairment in patients who received TDF based regimens. They observed a greater risk of renal impairment in patients receiving a ritonavir-boosted protease inhibitor.
7. Y.Cao, Y.Han, J.Xie, et al. Impact of a tenofovira disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicentre study. BMC Infect Dis. 2013;13(1):301.•• There was greater risk of renal impairment in patients who received TDF with a ritonavir-boosted protease inhibitor. The authors recommended closer monitoring of patients taking a regimen with these medicines.
8. I.Sabolic, A.R.Asif, W.E.Budach, et al. Gender differences in kidney function. Pflugers Arch. 2007;3(455):397–429.
9. A.S.Ray, T.Cihlar, K.L.Robinson, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50(10):3297–3304. doi:10.1128/AAC00251-06.• The mechanism by which TDF is extruded from the tubular cells to the luminal compartment of the proximal tubule is explained. MRP-4 on the apical side of the proximal tubule is explained as the key transporter that effluxes TDF into the lumen. The authors also highlight that an inhibitor of MRP-4 can result in accumulation of TDF.
10. I.F.Grigby. Tenofovir-associated bone density loss. Ther Clin Risk Manag. 2010;6:41–47.
11. D.M.Moss, M.Neary, A.Owen. The role of drug transporters in the kidney: lessons from tenofovir. Front Pharmacol. 2014;5:248.
12. B.P.Kearney, A.Mathias, A.Mittan, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;3(43):278–283.• This paper presents information on the factors associated with TDF-associated renal impairment.
13. J.J.Kiser, M.L.Carten, C.L.Aquilante, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir. Clin Pharmacol Ther. 2008 Feb;2(83):265–272.•• This paper provides pharmacokinetics evidence of increased area under the curve of TDF when co-administered with ritonavir-boosted LPV. However, the writers say that the TDF’s increased AUC did not have any clinical significance.
14. J.C.Yombi, A.Pozniak, M.Boffito, et al. Antiretroviral and the kidneys in current clinical practice. AIDS. 2014;5(28):621–632.•• The writers of this paper explain the slower rate of excretion of TDF when co-administered with LPV/r, but they questioned the clinical significance of the slowed excretion.
15. L.Sorli Maria, G.Ana, M.Milagro, et al. Chronic kidney disease prevalence and risk factors among HIV-infected patients. J Acquir Immune Defic Syndr. 2008;48(4):506–508.
16. M.J.Sarnak, A.S.Levey, A.C.Shoolwerth, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation. J Am Heart Assoc. 2003; 108:2154–2169.
17. D.M.Fine, J.E.Gallant. Nephrotoxicity of antiretroviral agents: is the list getting longer? J Infect Dis. 2013;207:1349–1351.
18. H.Bygrave, K.Kranzer, K.Hilderbrand, et al. Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural lesotho. PLoS One. 2011;6(3):e17609. doi:10.1371/journal.pone.0017609.
19. A.Mocroft, J.D.Lundgren, M.Ross, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2015;3(1):e23–e32.• The authors highlight the fact that long-term use of antiretroviral therapy increases adverse drug reactions with the kidneys at risk of being damaged by the large amount of drugs that reach them. The authors also highlight that the physiological processes of water reabsorption leave a high concentration of toxins in the tubules, which is an environment toxic to the epithelial cells.
20. J.R.Weinstein, S.Anderson. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17(4):302–307. doi:10.1053/j.ackd.2010.05.002.
21. L.Mulenga, P.Musonda, A.Mwango, et al. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia. Clin Infect Dis. 2014;58:1473–1480.
22. Department: Health, Republic of South Africa. The South African antiretroviral treatment guidelines. Pretoria: Department of Health, South Africa; 2013. p. 11–13.
23. J.E.Gallant, R.D.Moore. Renal function with use of a tenofovir-containing initial antiretroviral regimen. Aids. 2009;Sep 24;23(15):1971–1975. doi:10.1097/QAD.0b013e32832c96e9.
24. M.Goicoechea, S.Liu, B.Best, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197(1):102–108.
25. Gilead Sciences Incorporated. Tenofovir disoproxil fumarate prescribing information. Foster City (CA): Gilead Sciences, Inc.; 2013. Available from: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/viread/viread_pi.pdf
26. M.E.Lascano, E.D.Poggio. Kidney function assessment by creatinine based estimation equations [Internet]. 2010. [cited 2016 Mar 14]. Available from: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/nephrology/kidney-function/